secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001558370-25-006852
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio reports Q1 net loss $13.3M, cash $89.1M; AbbVie deal provides $52M upfront
--------------------------------------------------------------------------------

- Net loss $13.3M for Q1 2025, vs $17.2M Q1 2024.
- Cash $89.1M as of Mar 31, 2025, up from $55.3M at Dec 31, 2024, driven by $52M AbbVie upfront.
- R&D expenses $8.3M (down from $10.4M); G&A $8.5M (up from $6.1M) year-over-year.
- Updated Phase 2 data for vilastobart + atezolizumab in MSS CRC to be presented at ASCO 2025 (abstract 3553).
- First development candidates for masked T cell engagers (PSMA, CLDN18.2, STEAP1) expected H2 2025–H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025006852/0001558370-25-006852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025006852/xlo-20250508x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-006852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer